SciNeuro Acquires Rights to Lp-PLA2 Inhibitor from GSK for Alzheimer’s
publication date: Jun 1, 2022
SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerative diseases from GlaxoSmithKline. In clinical trials, the inhibitors have shown potential to improve cognitive function in Alzheimer’s Disease patients. SciNeuro will have worldwide rights to the inhibitors and will advance them through clinical proof of concept, at which point GSK has the right to reclaim global rights to the candidate (ex-China). Lp-PLA2 inhibitors are being developed to reduce inflammation in coronary heart diseases, Alzheimer's and diabetic macular edema. GSK's LpPLA2 inhibitor is in a Phase III trial for coronary heart disease. More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.